Reza J. Mehran

The University of Texas MD Anderson Cancer Center

Papers

8

Total Citations

321

H-Index

8

About

Dr. Reza J. Mehran is a leading thoracic surgeon whose research centers on three pivotal areas: optimizing surgical outcomes for non-small cell lung cancer (NSCLC), advancing minimally invasive robotic techniques, and refining perioperative care through enhanced recovery pathways. His most impactful work stems from the NEOSTAR trial, where he demonstrated that neoadjuvant nivolumab, alone or with ipilimumab, is safe and feasible before NSCLC resection—a finding that has reshaped preoperative immunotherapy protocols (94 citations, 2022). Dr. Mehran has also been instrumental in establishing robotic-assisted lobectomy as a standard approach, with a comprehensive institutional experience (92 citations, 2019) and analyses of segmentectomy trends (32 citations, 2021). Beyond the operating room, he has pioneered pain management strategies within enhanced recovery after surgery (ERAS) programs, achieving sustained reductions in opioid prescriptions (38 citations, 2016; 9 citations, 2021). His work on persistent opioid use in Medicare patients (9 citations, 2023) further underscores his commitment to patient-centered outcomes. With over 300 cumulative citations, Dr. Mehran’s contributions bridge surgical innovation, immunotherapy integration, and recovery optimization, making him a pivotal figure in modern thoracic oncology.

Research Focus

Key Achievements

8
H-Index
8
Papers
321
Total Citations
40
Avg Citations/Paper
🏆 Most Cited Paper
Surgical outcomes after neoadjuvant nivolumab or nivolumab with ipilimumab in patients with non–small cell lung cancer
94 citations · 2022
📈 Most Prolific Year: 2019 (2 Papers)
🤝 Key Collaborators: 54
🏛 Institutions: The University of Texas MD Anderson Cancer Center

Top Papers

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago